MEDINET Co., Ltd. (JP:2370)
:2370
Top Page
MEDINET Co., Ltd.
(2370)
Select Model
Select Model
Rating:46Neutral
Price Target:
¥31.00
▲(6.90% Upside)
Action:ReiteratedDate:01/07/26
The score is held down primarily by very weak financial performance driven by ongoing large losses and deteriorating free cash flow, despite low leverage. Technicals are mixed with modest near-term strength but a still-weak trend signal (negative MACD), and valuation is constrained by losses and lack of dividend support.
Positive Factors
Recurring & diversified revenue streams
MEDINET's mix of hardware sales plus software, maintenance, training and partnership revenue builds recurring income from installed systems. This durable business model increases revenue visibility, supports higher lifetime customer value and cushions hardware cyclicality for months ahead.
Negative Factors
Persistent large losses
Net margin near -168% in FY2025 reflects deep, sustained losses that erode equity and restrict reinvestment capacity. Structural unprofitability suggests issues with pricing, cost base or product mix; absent a credible path to sustained profits, the company will need financing or major operational changes.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring & diversified revenue streams
MEDINET's mix of hardware sales plus software, maintenance, training and partnership revenue builds recurring income from installed systems. This durable business model increases revenue visibility, supports higher lifetime customer value and cushions hardware cyclicality for months ahead.
Read all positive factors
MEDINET Co., Ltd. (2370) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥7.99B
Dividend YieldN/A
Average Volume (3M)1.57M
Price to Earnings (P/E)―
Beta (1Y)0.50
Revenue Growth5.44%
EPS Growth-2.17%
CountryJP
Employees92
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.28
Shares Outstanding275,517,330
10 Day Avg. Volume1,137,840
30 Day Avg. Volume1,567,416
Financial Highlights & Ratios
PEG Ratio-3.12
Price to Book (P/B)2.45
Price to Sales (P/S)11.43
P/FCF Ratio-6.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MEDINET Co., Ltd. Business Overview & Revenue Model
Company Description
MEDINET Co., Ltd. operates as a contract development and manufacturing organization that provides regenerative medicine and cell therapy solutions in Japan. Its solutions include technical know-how, facilities, systems, materials, professional cel...
How the Company Makes Money
MEDINET generates revenue primarily through the sale of its medical imaging systems and diagnostic tools, which are utilized by hospitals and clinics across various healthcare settings. The company also earns income from software solutions that en...
MEDINET Co., Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
15
Very Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 724.63M | 810.29M | 768.50M | 661.54M | 633.67M | 683.03M |
| Gross Profit | 128.40M | 83.44M | 82.67M | 65.21M | 90.44M | 135.45M |
| EBITDA | -1.29B | -1.34B | -1.27B | -1.35B | -1.25B | -960.77M |
| Net Income | -1.41B | -1.36B | -1.28B | -1.44B | -1.25B | -843.40M |
Balance Sheet | ||||||
| Total Assets | 6.35B | 4.25B | 5.70B | 5.63B | 6.08B | 5.38B |
| Cash, Cash Equivalents and Short-Term Investments | 5.03B | 3.17B | 4.65B | 4.40B | 4.50B | 4.10B |
| Total Debt | 91.32M | 0.00 | 781.00K | 2.31M | 4.30M | 7.69M |
| Total Liabilities | 548.63M | 477.10M | 509.95M | 590.60M | 566.58M | 475.44M |
| Stockholders Equity | 5.80B | 3.78B | 5.19B | 5.04B | 5.51B | 4.90B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -1.44B | -1.25B | -1.28B | -1.14B | -633.51M |
| Operating Cash Flow | 0.00 | -1.41B | -1.19B | -1.26B | -1.13B | -612.08M |
| Investing Cash Flow | 0.00 | -565.17M | -12.71M | -2.16M | -50.35M | -18.38M |
| Financing Cash Flow | 0.00 | -2.55M | 1.46B | 1.16B | 1.58B | 1.08B |
MEDINET Co., Ltd. Technical Analysis
Negative
29.00
Price Trends
30.86
Negative
30.77
Negative
33.72
Negative
Market Momentum
-0.44
Positive
41.15
Neutral
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2370, the sentiment is Negative. The current price of 29 is below the 20-day moving average (MA) of 30.25, below the 50-day MA of 30.86, and below the 200-day MA of 33.72, indicating a bearish trend. The MACD of -0.44 indicates Positive momentum. The RSI at 41.15 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:2370.
MEDINET Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | ¥4.59B | -828.32 | ― | ― | -0.77% | -288.43% | |
53 Neutral | ¥6.30B | 19.71 | ― | 2.08% | -10.24% | ― | |
52 Neutral | ¥6.03B | -2.65 | ― | 5.44% | -15.42% | -879.08% | |
52 Neutral | ¥138.24B | -8.84 | ― | 2.18% | -0.16% | -802.20% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | ¥7.09B | -5.04 | ― | ― | ― | ― | |
46 Neutral | ¥7.99B | -5.66 | ― | ― | 5.44% | -2.17% |
* Healthcare Sector Average
JP:2370
MEDINET Co., Ltd.
29.00
-6.00
-17.14%
JP:2183
Linical Co., Ltd.
267.00
-53.00
-16.56%
JP:2342
Trans Genic Inc.
272.00
89.00
48.63%
JP:2385
Soiken Holdings Inc.
241.00
98.25
68.83%
JP:4974
Takara Bio Inc.
1,148.00
320.00
38.65%
JP:206A
PRISM BioLab Co. LTD
192.00
-88.00
-31.43%
MEDINET Co., Ltd. Corporate Events
MEDINET Widens Losses but Maintains Strong Equity Base in Q1 FY2026
Feb 13, 2026
MEDINET Co., Ltd. reported first-quarter net sales of ¥181 million for the period ended December 2025, down 11.4% year-on-year, continuing a decline from the prior year’s 17.7% drop. The company remained loss-making, with an operating l...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.